This study used a large US claims database to estimate the effects of disease progression on healthcare resource utilization (HRU) and costs among multiple myeloma (MM) patients who received their first stem cell transplant (SCT) within 1 year of diagnosis and had ≥1 line of therapy (LOT). Disease progression was defined as advancement to the next LOT, bone metastasis, hypercalcemia, soft tissue plasmacytoma, skeletal-related events, acute kidney disease, or death within 12 months of LOT initiation. Inverse probability of treatment weighting was used to adjust for baseline characteristic differences between patients with and without progression. Patients with progression had significantly higher annual hospitalizations and healthcare costs across all LOTs (L1-L3). Incremental annual costs were substantial, varying by LOT and time period.

Rafael Fonseca, May Hagiwara, Sumeet Panjabi, Emre Yucel, Jacqueline Buchanan, Thomas Delea